rs11045585
| Orientation | plus |
| Stabilized | plus |
| Geno | Mag | Summary |
|---|---|---|
| (A;A) | 2 | 24% chance (lower than average) of docetaxel-induced leukopenia/neutropenia |
| (A;G) | 2 | 63% chance (higher than average) of docetaxel-induced leukopenia/neutropenia |
| (G;G) | (no data; implied high chance of docetaxel-induced leukopenia/neutropenia) |
| Reference | GRCh38 38.1/141 |
| Chromosome | 12 |
| Position | 20892760 |
| Gene | SLCO1B3 |
| is a | snp |
| is | mentioned by |
| dbSNP | rs11045585 |
| dbSNP (classic) | rs11045585 |
| ClinGen | rs11045585 |
| ebi | rs11045585 |
| HLI | rs11045585 |
| Exac | rs11045585 |
| Gnomad | rs11045585 |
| Varsome | rs11045585 |
| LitVar | rs11045585 |
| Map | rs11045585 |
| PheGenI | rs11045585 |
| Biobank | rs11045585 |
| 1000 genomes | rs11045585 |
| hgdp | rs11045585 |
| ensembl | rs11045585 |
| geneview | rs11045585 |
| scholar | rs11045585 |
| rs11045585 | |
| pharmgkb | rs11045585 |
| gwascentral | rs11045585 |
| openSNP | rs11045585 |
| 23andMe | rs11045585 |
| SNPshot | rs11045585 |
| SNPdbe | rs11045585 |
| MSV3d | rs11045585 |
| GWAS Ctlg | rs11045585 |
| GMAF | 0.1662 |
| Max Magnitude | 2 |
| ? | (A;A) (A;G) (G;G) | 28 |
|---|---|---|
|
| ||
[PMID 18294295] rs12762549 and rs11045585 can be used to predict whether docetaxel will induce leukopenia/neutropenia, according to a study of ~100 Japanese patients. When patients were classified into three groups by the scoring system based on the genotypes of these two SNPs, patients with a score of 1 or 2 were shown to have a significantly higher risk of docetaxel-induced leukopenia/neutropenia as compared to those with a score of 0 (P = 0.0000057; odds ratio [OR], 7.00; 95% CI [confidence interval], 2.95-16.59). This prediction system correctly classified 69.2% of severe leukopenia/neutropenia and 75.7% of non-leukopenia/neutropenia into the respective categories.
[Effect percentages provided in table are raw population fractions taken from the referenced study based on rs11045585 only. Total population size = 113. Breakdown: leukopenia/neutropenia: AA=20 AG=19; non-leukopenia/neutropenia: AA=63 AG=11]
[PMID 21691256] Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose
[PMID 21468756] The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
[PMID 21673613] The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers.
[PMID 21829131] The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers.
[PMID 25648089
] Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy
[PMID 26475344] CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer
